替吉奥胶囊对老年晚期胃癌患者的不良反应评价及其用药护理
|
摘要
目的探讨替吉奥胶囊对老年晚期胃癌患者的不良反应,并归纳其用药护理方法。方法选择老年晚期胃癌患者56例作为本次研究对象,均采用替吉奥进行治疗,给药剂量为40~60mg/次,早晚两次,口服给药,连续给药治疗4周后休息2周,每6周为一个周期,治疗持续1~4个周期。从开始用药后即观察患者不良反应发生情况,并给予饮食、用药及心理护理干预指导。结果替吉奥胶囊对老年晚期胃癌患者的治疗有效率为85.71%;治疗后患者KPS评分明显提高,差异有统计学意义(P<0.05);48例患者出现不同程度的毒副反应:消化道不良反应35例;血液毒性(骨髓抑制)反应19例;皮肤毒性反应41例;谷丙转氨酶升高21例,毒副反应多分布于Ⅰ~Ⅱ度。结论替吉奥胶囊具有良好的临床疗效,但存在相应毒副反应,故治疗期间医护人员需注意给予相应护理干预,保证治疗按计划进行。
Objective To investigate the adverse effects of Tegafur Gimeracil Oteracil Potassium Capsule on elderly patients with advanced gastric cancer and to summarize medication nursing methods. Methods 56 elderly patients with advanced gastric cancer were selected as the subjects.Patients were treated with Gimeracil and Oteracil Porassium.The dosage was 40-60 mg/times,two times sooner or later,orally administered.After 4 weeks of continuous treatment,the interval was 2 weeks,one cycle every 6 weeks,and the treatment lasted for 1-4 cycles.The occurrence of adverse reactions in patients from the beginning of the medication were observed.And diet,medication and psychological nursing intervention guidance were given. Results The effective rate of Tegafur Gimeracil Oteracil Potassium Capsule for the patients with advanced gastric cancer was 85.71%.After treatment,KPS score was significantly improved,and the difference was statistically significant(P < 0.05);48 patients suffered from varying degrees of toxic and side effects,including 35 cases of adverse reactions of digestive tract;blood toxicity(myelosuppression) reaction in 19 cases;41 cases of skin toxicity;21 patients with elevated alanine aminotransferase,toxicities were distributed in I-II degree. Conclusion Tegafur Gimeracil Oteracil Potassium Capsule has good clinical efficacy,but it has corresponding adverse reactions,so the medical staff should pay attention to the corresponding nursing intervention during the treatment period to ensure that the treatment is carried out according to plan.
Objective To investigate the adverse effects of Tegafur Gimeracil Oteracil Potassium Capsule on elderly patients with advanced gastric cancer and to summarize medication nursing methods. Methods 56 elderly patients with advanced gastric cancer were selected as the subjects.Patients were treated with Gimeracil and Oteracil Porassium.The dosage was 40-60 mg/times,two times sooner or later,orally administered.After 4 weeks of continuous treatment,the interval was 2 weeks,one cycle every 6 weeks,and the treatment lasted for 1-4 cycles.The occurrence of adverse reactions in patients from the beginning of the medication were observed.And diet,medication and psychological nursing intervention guidance were given. Results The effective rate of Tegafur Gimeracil Oteracil Potassium Capsule for the patients with advanced gastric cancer was 85.71%.After treatment,KPS score was significantly improved,and the difference was statistically significant(P < 0.05);48 patients suffered from varying degrees of toxic and side effects,including 35 cases of adverse reactions of digestive tract;blood toxicity(myelosuppression) reaction in 19 cases;41 cases of skin toxicity;21 patients with elevated alanine aminotransferase,toxicities were distributed in I-II degree. Conclusion Tegafur Gimeracil Oteracil Potassium Capsule has good clinical efficacy,but it has corresponding adverse reactions,so the medical staff should pay attention to the corresponding nursing intervention during the treatment period to ensure that the treatment is carried out according to plan.
引文
[1]宋杰,陈凤格,赵伟,等.胃癌的发病率现状与治疗研究进展[J].中国慢性病预防与控制,2016,24(9):704-707.
[2]高炜,徐艳霞,梁华,等.替吉奥对比卡培他滨一线治疗老年晚期胃癌的疗效分析[J].实用老年医学,2012,26(6):501-503,506.
[3]Diamantis N,Banerji U.Antibody-drug conjugates—an emerging class of cancer treatment[J].British Journal of Cancer,2016,114(4):362-367.
[4]李丽,高益琴,方伟红,等.奥沙利铂联合替吉奥治疗晚期胃癌毒副反应的观察及护理[J].护理与康复,2011,10(12):1092-1093.
[5]周子娇,王晓红.替吉奥胶囊治疗胃癌的疗效观察及对相关肿瘤标志物的影响[J].海南医学院学报,2013,19(6):775-777.
[6]吴福道,张小静,蔡辉,等.替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效观察[J].重庆医学,2015,44(13):1835-1837.
[7]李竟长,陈日新,朱州.替吉奥胶囊联合奥沙利铂治疗老年晚期胃癌的近期疗效[J].右江医学,2013,41(2):181-183.
[8]杨冰.晚期胃癌营养不良患者的综合护理干预效果[J].实用临床医药杂志,2016,20(18):184-185.
[9]喻志艳,徐丹,邓前红,等.心理干预对晚期胃癌化疗患者负性心理及生活质量的影响[J].齐鲁护理杂志,2013,19(21):13-14.
[10]周富莲,梁玉芬.护理干预对胃癌化疗患者焦虑的影响[J].河北医药,2013,39(19):3032-3033.
[11]钟小华.奥沙利铂为主联合其他药物化疗治疗晚期胃癌的临床疗效及护理[J].中国实用护理杂志,2012,28(30):69-70.
[12]钟东塔,施纯玫,林动.替吉奥胶囊联合奥沙利铂治疗晚期胃癌26例疗效分析[J].福建医药杂志,2012,34(1):99-101.
[13]徐枝霞.胃癌化疗后致重度骨髓抑制继发出血和红皮病1例的护理[J].护理与康复,2015,14(12):1187-1188.
[14]樊鑫鑫,吕慧芳,陈贝贝,等.替吉奥单药治疗老年晚期胃癌的临床观察[J].中国现代医生,2016,54(18):82-85.
[15]王荣.整体护理干预在预防晚期胃癌患者不良反应中的应用[J].齐鲁护理杂志,2014,20(10):45-47.
[16]王园园,宁琳,李小宁,等.人性照护理论对中晚期胃癌化疗患者的护理效果分析[J].昆明医科大学学报,2015,36(8):169-171.
[2]高炜,徐艳霞,梁华,等.替吉奥对比卡培他滨一线治疗老年晚期胃癌的疗效分析[J].实用老年医学,2012,26(6):501-503,506.
[3]Diamantis N,Banerji U.Antibody-drug conjugates—an emerging class of cancer treatment[J].British Journal of Cancer,2016,114(4):362-367.
[4]李丽,高益琴,方伟红,等.奥沙利铂联合替吉奥治疗晚期胃癌毒副反应的观察及护理[J].护理与康复,2011,10(12):1092-1093.
[5]周子娇,王晓红.替吉奥胶囊治疗胃癌的疗效观察及对相关肿瘤标志物的影响[J].海南医学院学报,2013,19(6):775-777.
[6]吴福道,张小静,蔡辉,等.替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效观察[J].重庆医学,2015,44(13):1835-1837.
[7]李竟长,陈日新,朱州.替吉奥胶囊联合奥沙利铂治疗老年晚期胃癌的近期疗效[J].右江医学,2013,41(2):181-183.
[8]杨冰.晚期胃癌营养不良患者的综合护理干预效果[J].实用临床医药杂志,2016,20(18):184-185.
[9]喻志艳,徐丹,邓前红,等.心理干预对晚期胃癌化疗患者负性心理及生活质量的影响[J].齐鲁护理杂志,2013,19(21):13-14.
[10]周富莲,梁玉芬.护理干预对胃癌化疗患者焦虑的影响[J].河北医药,2013,39(19):3032-3033.
[11]钟小华.奥沙利铂为主联合其他药物化疗治疗晚期胃癌的临床疗效及护理[J].中国实用护理杂志,2012,28(30):69-70.
[12]钟东塔,施纯玫,林动.替吉奥胶囊联合奥沙利铂治疗晚期胃癌26例疗效分析[J].福建医药杂志,2012,34(1):99-101.
[13]徐枝霞.胃癌化疗后致重度骨髓抑制继发出血和红皮病1例的护理[J].护理与康复,2015,14(12):1187-1188.
[14]樊鑫鑫,吕慧芳,陈贝贝,等.替吉奥单药治疗老年晚期胃癌的临床观察[J].中国现代医生,2016,54(18):82-85.
[15]王荣.整体护理干预在预防晚期胃癌患者不良反应中的应用[J].齐鲁护理杂志,2014,20(10):45-47.
[16]王园园,宁琳,李小宁,等.人性照护理论对中晚期胃癌化疗患者的护理效果分析[J].昆明医科大学学报,2015,36(8):169-171.